Ambrx Biopharma Inc. (AMAM) Financials

AMAM Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2023 271.5 million 29.1 million
June 30, 2023 279.9 million 29.6 million
March 31, 2023 210.6 million 28.0 million
Dec. 31, 2022 147.0 million 29.1 million

AMAM Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -19.2 million 4.8 million
June 30, 2023 -13.9 million 2.9 million
March 31, 2023 -13.0 million 1.9 million
Dec. 31, 2022 -12.8 million 1.2 million

AMAM Net Income

No data available :(

AMAM Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 225.3 million - 10.5 million
June 30, 2023 235.1 million - 11.0 million
March 31, 2023 157.5 million - 11.5 million
Dec. 31, 2022 84.5 million - 12.0 million

AMAM Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 62.3 million
June 30, 2023 55.9 million
March 31, 2023 45.0 million
Dec. 31, 2022 38.6 million

AMAM Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 298000 16.3 million 9.4 million -
June 30, 2023 783000 14.4 million 5.9 million -
March 31, 2023 783000 9.8 million 6.1 million 1.3 million
Dec. 31, 2022 47000 10.3 million 5.6 million 681500

AMAM Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 53000 -
June 30, 2023 1.1 million -
March 31, 2023 24000 -
Dec. 31, 2022 2.2 million -

AMAM

Price: $28

52 week price:
4.45
28.15

Earnings Per Share: 0.42 USD

P/E Ratio: 66.14

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 261163

Market Capitalization: 1.8 billion

Links: